Holen Sie sich die Stockscreener-App
53.88
3.16%
1.65
Handel nachbörslich:
53.99
0.11
+0.20%
Schlusskurs vom Vortag:
$52.23
Offen:
$52.25
24-Stunden-Volumen:
1.27M
Relative Volume:
1.85
Marktkapitalisierung:
$2.60B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$123.81M
KGV:
22.36
EPS:
2.41
Netto-Cashflow:
$20.35M
1W Leistung:
-28.89%
1M Leistung:
-28.65%
6M Leistung:
-13.50%
1J Leistung:
-27.45%
1-Tages-Spanne:
$51.83
$54.06
1-Wochen-Bereich:
$50.68
$72.15
52-Wochen-Spanne:
$50.68
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Vergleichen Sie HAE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
53.88 | 2.52B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Is Haemonetics Corporation stock entering bullish territory2025 Geopolitical Influence & Long Hold Capital Preservation Plans - Newser
Advanced analytics toolkit walkthrough for Haemonetics CorporationGap Up & Weekly High Conviction Ideas - Newser
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript - Insider Monkey
Is Haemonetics Corporation meeting your algorithmic filter criteriaDaily Investment Ideas with Market Insight - Newser
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE) - Seeking Alpha
Understanding Haemonetics (HAE) Reliance on International Revenue - Yahoo Finance
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown - Investing.com
Haemonetics’ (HAE) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Mizuho Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Haemonetics Corporation stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Haemonetics (NYSE:HAE) Receives “Buy” Rating from Needham & Company LLC - Defense World
Barrington Research Lowers Haemonetics (NYSE:HAE) Price Target to $86.00 - Defense World
Haemonetics (NYSE:HAE) Earns “Buy” Rating from Needham & Company LLC - Defense World
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $62 to $86 - 富途牛牛
Detecting price anomalies in Haemonetics Corporation with AIFree Trade Ready Stock Watch for Short Term - Newser
What makes Haemonetics Corporation stock price move sharplyAI Swing Strategy Signal Forecasting System - Newser
How to escape a deep drawdown in Haemonetics CorporationBuy Point Strategy with Profit Protection - Newser
Haemonetics Reports Q1 Fiscal 2026 Earnings - The Globe and Mail
JP Morgan Downgrades Haemonetics (HAE) - MSN
Haemonetics Corporation stock trendline breakdownFree Breakout Confirmation With Entry Tracker - Newser
Haemonetics Corp Reports Strong Organic Growth Despite Portfolio Transitions - AInvest
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Benzinga
Haemonetics (HAE): Mizuho Lowers Price Target to $70.00 While Ma - GuruFocus
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Technical signs of recovery in Haemonetics CorporationSummary of Consistent Growth Stock Picks - Newser
Haemonetics: Fiscal Q1 Earnings Snapshot - Connecticut Post
Haemonetics stock rating cut by JPMorgan on mixed results - Investing.com
Haemonetics (NYSE:HAE) Shares Down 22.1% Following Analyst Downgrade - Defense World
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Corp (HAE) Analysts Lower Price Target to $68, Maintain "Buy" Rating - AInvest
Haemonetics (NYSE:HAE) Surprises With Strong Q2 But Stock Drops 24% - Yahoo Finance
Analyst Needham Lowers Price Target for Haemonetics (HAE) to $68 - GuruFocus
Haemonetics stock price target lowered to $68 at Needham on competition - Investing.com Canada
Earnings call transcript: Haemonetics beats Q1 2026 earnings, stock drops - Investing.com
Haemonetics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Haemonetics Corporation Reports Earnings Results for the First Quarter Ended June 28, 2025 - MarketScreener
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Haemonetics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Haemonetics (HAE) Q1 Revenue Falls 4% - The Motley Fool
Haemonetics Corp Q1 Fiscal 2026 Earnings: Revenue Surpasses Esti - GuruFocus
Haemonetics' Q1 2025 Earnings: Strategic Resilience and Long-Term Value Amid Plasma Challenges - AInvest
Haemonetics Corporation Q1 Fiscal 2026 Results - TradingView
HAEMONETICS CORP SEC 10-Q Report - TradingView
Haemonetics Q1 FY26 Earnings Released Today: Join Live Conference Call for Full Analysis - Stock Titan
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
What makes Haemonetics Corporation stock attractive to long term investorsCapital Protection Strategy With Risk Analysis - Newser
Brokerages Set Haemonetics Corporation (NYSE:HAE) Price Target at $97.30 - Defense World
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Why Haemonetics Corporation stock attracts strong analyst attentionCapital Safe Picks with Consistent Gains - Newser
Analyzing net buyer seller activity in Haemonetics CorporationDownside Control Plan With Support Analysis - Newser
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):